Mylan Specialty and Pfizer Announce Licensing Agreement for EpiPen® Injection 0.3/0.15mg in Japan
12:11 EDT 7 Aug 2012 | PR Newswire
This article has expired, however you can still
download the PDF.
Preview:
BASKING RIDGE, N.J. and NEW YORK, Aug. 7, 2012 /PRNewswire/ -- Mylan Specialty L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), and Pfizer Inc. (NYSE: PFE) today announced a license agreement, under which Pfizer will obtain the exclusive rights to mark...
Other Sources for this Article
More From BioPortfolio on "Mylan Specialty and Pfizer Announce Licensing Agreement for EpiPen® Injection 0.3/0.15mg in Japan"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
